US2001051602A1PendingUtilityA1
Methods for increasing ApoE levels for the treatment of neurodegenerative disease
Priority: Sep 24, 1997Filed: Jun 22, 2001Published: Dec 13, 2001
Est. expirySep 24, 2017(expired)· nominal 20-yr term from priority
Inventors:Judes Poirier
A61P 25/28A61P 25/00A61P 25/02A61P 25/16A61P 25/14A61K 31/366A61P 21/00A61K 45/06A61K 31/10A61K 31/407
43
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein is a method for reducing neurodegenerative disease in patients by administration of a therapeutically-effective amount of a compound which can increase ApoE levels.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating a neuronal deficit in a patient, said patient diagnosed with a neurodegenerative disease or a predisposition to a neurodegenerative disease, said method comprising administering a therapeutically-effective amount of a composition other than tacrine, donepezil, or estrogen, said composition being a composition which increases ApoE levels.
2 . The method of claim 1 , wherein, said neurodegenerative disease is a disease other than AD.
3 . The method of claim 1 , wherein said neurodegenerative disease is a disease other than stroke.
4 . The method of claim 1 , wherein said composition comprises a compound selected from the group comprising probucol, heptylphysostigmine, simvastatin, lovastatin, pravastatin, and thorvastatin.
5 . A method of treating a neuronal deficit in a patient, said patient diagnosed with a non-Alzheimer's neurodegenerative disease or a predisposition to a non-Alzheimer's neurodegenerative disease, said method comprising administering a therapeutically effective amount of a composition which increases ApoE levels.
6 . The method of claim 5 , wherein said composition comprises a compound selected from the group comprising probucol, tacrine, heptylphysostigmine, simvastatin, lovastatin, pravastatin, thorvastatin, and steroids.
7 . The method of claim 5 , wherein said composition comprises estrogen.
8 . The method of claim 1 , wherein said method includes administering a second compound, said second compound selected from the group comprising probucol analogs, vitamin E, donepezil, blood pressure inhibitors, antioxidants, anti-inflammatories, or steroids other than estrogen.
9 . The method of claim 5 , wherein said method includes administering a second compound, said second compound selected from the group comprising probucol analogs, tacrine, vitamin E, donepezil, blood pressure inhibitors, antioxidants, anti-inflammatories, or steroids.
10 . The method of claims 1 or 5 , wherein said amount of a composition is sufficient to increase ApoE levels in said patient.
11 . The method of claim 10 , wherein said amount of a composition is sufficient to increase ApoE levels by about 10% or more.
12 . The method of claims 1 or 5 , wherein said amount of a composition is sufficient to increase amyloid scavenging by ApoE.
13 . The method of claims 1 or 5 , wherein said patient has a disease of the central nervous system.
14 . The method of claims 1 or 5 , wherein said patient has a disease of the peripheral nervous system.
15 . The method of claims 1 or 5 , wherein said patient is presymptomatic.
16 . The method of claims 1 or 5 , wherein said patient has at least one apoE4 allele.
17 . The method of claims 1 or 5 , wherein said patient has been diagnosed to suffer from, Creutzfeldt-Jakob disease, Huntington's disease, Lewy body disease, Parkinson's disease, Pick's disease, amyotrophic lateral sclerosis, neurofibromatosis, brain injury, stroke, multiple sclerosis, or multiple infarct dementia.
18 . The method of claim 1 , wherein said patient has been diagnosed to suffer from Alzheimer's disease.
19 . The method of claims 1 or 5 , wherein said patient is genetically predisposed to suffer from a disease selected from the group consisting of Creutzfeldt-Jakob disease, Huntington's disease, Lewy body disease, Parkinson's disease, Pick's disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, multiple infarct dementia, and neurofibromatosis.
20 . The method of claim 1 , wherein said patient is genetically predisposed to suffer from Alzheimer's disease.
21 . The method of claim 1 , wherein said administering further includes administering tacrine to said patient.
22 . The method of claim 1 , wherein said administering further includes administering estrogen to said patient.
23 . The method of claim 1 , wherein said administering further includes administering donepezil to said patient.
24 . A method of increasing ApoE polypeptide levels in a patient, said method comprising administering a therapeutically-effective amount of a composition comprising probucol or an analog of probucol.
25 . The method of claim 24 , wherein said patient has a neurodegenerative disease.
26 . The method of claim 24 , wherein said patient has a disease of the central nervous system.
27 . The method of claim 24 , wherein said patient has a disease of the peripheral nervous system.
28 . The method of claim 24 , wherein said patient is suffering from Alzheimer's disease.
29 . The method of claim 24 , wherein said patient is genetically predisposed to suffer from Alzheimer's disease.
30 . The method of claim 24 , wherein said patient has at least one apoE4 allele.
31 . The method of claim 24 , wherein said patient is suffering from Creutzfeldt-Jakob disease, Huntington's disease, Lewy body disease, Parkinson's disease, Pick's disease, amyotrophic lateral sclerosis, neurofibromatosis, brain injury, stroke, multiple sclerosis, or multiple infarct dementia.
32 . The method of claim 24 , wherein said patient is genetically predisposed to suffer from a disease selected from the group consisting of Creutzfeldt-Jakob disease, Huntington's disease, Lewy body disease, Parkinson's disease, Pick's disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, multiple infarct dementia, and neurofibromatosis.
33 . The method of claim 24 , wherein said therapeutically effective amount of a composition may comprise a compound selected from the group comprising probucol analogs, tacrine, heptylphysostigmine, simvastatin, lovastatin, pravastatin, thorvastatin, vitamin E, donepezil, blood pressure inhibitors, antioxidants, anti-inflammatories, and steroids.
34 . The method of claim 24 , wherein said composition further includes one or more compounds selected from the group comprising, vitamin E, donepezil, blood pressure inhibitors, antioxidants, anti-inflammatories, and steroids.
35 . The method of claim 24 , wherein said expression is measured by quantitating ApoE polypeptide levels.
36 . The method of claim 24 , wherein said expression is measured by quantitating ApoE polypeptide levels with an antibody.
37 . The method of claim 24 , wherein said increasing is in brain tissue or human cerebrospinal fluid of said patient.
38 . A method of identifying a therapeutic compound effective for the treatment of a neurodegenerative disease, said method comprising exposing a cell to a compound and measuring the expression of ApoE, an increase in said expression identifying a therapeutic compound.
39 . The method of claim 38 , wherein an increase ApoE levels by 10% or more indicates a therapeutic compound.
40 . The method of claim 38 , wherein said cell is an astrocyte, neuron, glial cell, oligodendrocyte, Schwann cell or any other cell derived from nervous system tissue.
41 . The method of claim 38 , wherein said cell is derived from nervous system tissue from a patient with, or predicted to suffer from, a neurodegenerative disease.
42 . The method of claim 38 , wherein said expression is measured by quantitating apoE mRNA levels.
43 . The method of claim 38 , wherein said expression is measured by quantitating ApoE polypeptide levels.Join the waitlist — get patent alerts
Track US2001051602A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.